Our Company

Redefining the treatment of hematologic diseases

PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs).

Rewriting treatment paradigms

We’re working to develop new hematology/oncology therapies by looking at a proven therapeutic concept with a fresh perspective. Drawing on our deep biopharmaceutical expertise, we’re aiming to transform the risk/benefit profiles of existing therapies. Our goal: to give physicians new therapeutic tools for early intervention—while giving new hope to patients with rare cancers.

Combining rigor with ingenuity

Our approach combines rigorous scientific research with innovative thinking. Our team is comprised of leading minds from some of the world’s most respected biopharmaceutical companies. Their pioneering expertise fuels our ability to challenge assumptions about existing treatment modalities, leading to transformative innovations.

How did it all start? →

Collaborating to make an impact

PharmaEssentia is working to reshape the treatment landscape through active collaboration with the global MPN community. We have built strong partnerships with world-class collaborators, including university research institutes and biotechnology and pharmaceutical companies, helping drive our rapid growth.

Besremi® is a registered trademark of PharmaEssentia Corporation.